Uveoretinitis – A Complete Patient Guide

Overview

Uveoretinitis (also called posterior uveitis with retinal involvement) refers to inflammation that affects both the uveal tract (the middle layer of the eye – iris, ciliary body, and choroid) and the retina. The condition can involve the vitreous humor, causing vitritis, and may affect the optic nerve. Inflammation can be acute or chronic and may lead to permanent vision loss if not treated promptly.

Although uveitis overall accounts for about 10–15% of all causes of legal blindness in the United States, posterior uveitis/uveoretinitis is less common than anterior uveitis. Epidemiologic data from the CDC and the International Uveitis Study Group estimate an annual incidence of approximately 10–15 cases per 100,000 people, with a slight predominance in adults aged 20–50 years. Both sexes are affected equally, but certain underlying systemic diseases (e.g., sarcoidosis, Behçet’s disease) show gender predilections.

Symptoms

Because inflammation is located in the posterior segment, symptoms may be subtle early on and progress rapidly. Common manifestations include:

• Decreased visual acuity – blurry or hazy vision that can develop over hours to days.
• Floaters – dark specks or cobweb‑like shapes that drift across the visual field.
• Photopsia – brief flashes of light, especially in peripheral vision.
• Redness of the eye – less pronounced than in anterior uveitis, but may be present.
• Pain – usually mild; severe pain suggests anterior involvement or secondary infection.
• Difficulty seeing in low light (nyctalopia) – due to retinal dysfunction.
• Loss of contrast sensitivity – colors may appear washed out.
• Field defects – peripheral blind spots or central scotomas.
• Distorted vision (metamorphopsia) – straight lines appear wavy, often due to macular edema.

Symptoms may be unilateral (one eye) or bilateral, depending on the underlying cause.

Causes and Risk Factors

Uveoretinitis is a manifestation rather than a disease itself. It can be triggered by infectious agents, systemic autoimmune disorders, or remain idiopathic.

Infectious Causes

• Toxoplasma gondii – the most common cause of infectious posterior uveitis worldwide.^[1]
• Toxocara canis – especially in children with pet exposure.
• Herpesviruses (HSV, VZV, CMV, EBV) – often in immunocompromised patients.
• Mycobacterium tuberculosis – ocular tuberculosis can mimic uveoretinitis.
• Syphilis, Lyme disease, and Bartonella henselae – important to rule out in atypical cases.

Non‑infectious (Autoimmune) Causes

• Sarcoidosis – systemic granulomatous disease; eye involvement in ~30% of patients.^[2]
• Behçet’s disease – more common in men from the Mediterranean and East Asia; relapsing posterior inflammation.
• Multiple sclerosis – optic neuritis may coexist with posterior uveitis.
• Vogt‑Koyanagi‑Harada (VKH) syndrome – autoimmune reaction against melanocytes, leading to diffuse choroiditis.
• Systemic lupus erythematosus (SLE) and Rheumatoid arthritis – less frequent but documented.

Other Risk Factors

• Age 20–50 years (peak incidence).
• Genetic predisposition – certain HLA alleles (e.g., HLA‑B51 in Behçet’s) increase risk.
• Immunosuppression – HIV/AIDS, organ transplantation, systemic steroids.
• Recent ocular trauma or intra‑ocular surgery (rarely precipitates inflammation).

Diagnosis

Timely, accurate diagnosis relies on a combination of clinical examination and targeted investigations.

Clinical Examination

• Visual acuity testing – baseline and monitoring.
• Slit‑lamp biomicroscopy – assesses anterior chamber cells/flare and vitreous haze.
• Fundus examination – indirect ophthalmoscopy to visualize retinal lesions, choroidal infiltrates, optic disc edema.
• Intra‑ocular pressure (IOP) measurement – helps differentiate from secondary glaucoma.

Imaging & Laboratory Tests

• Optical Coherence Tomography (OCT) – high‑resolution cross‑sectional images of retina and macula; detects edema or sub‑retinal fluid.
• Fluorescein Angiography (FA) – highlights retinal vascular leakage, indicative of active inflammation.
• Indocyanine Green Angiography (ICGA) – better for choroidal lesions.
• Ultrasound B‑scan – useful when media opacity (e.g., dense vitritis) limits view.
• Laboratory work‑up – tailored to suspected cause:
• Serology for Toxoplasma, Toxocara, syphilis (RPR/VDRL), Lyme (ELISA/Western blot).
• Quantiferon‑TB Gold or tuberculin skin test.
• ACE and lysozyme levels for sarcoidosis.
• HLA typing (e.g., HLA‑B51).
• CBC, ESR/CRP, ANA, anti‑dsDNA for systemic autoimmune disease.

In many cases, the diagnosis is “presumed” based on clinical pattern and epidemiology, with laboratory confirmation when available.

Treatment Options

Therapy aims to control inflammation, prevent tissue damage, and preserve vision. Treatment is individualized according to etiology, severity, and laterality.

1. Corticosteroids

• Topical steroids – limited role in posterior disease but may help anterior spill‑over.
• Periocular (sub‑Tenon) or intravitreal steroid injections – triamcinolone acetonide (4 mg) for rapid control of macular edema.
• Systemic oral prednisone – typical starting dose 0.5–1 mg/kg/day with gradual taper over weeks to months. Monitor blood pressure, glucose, and bone health.^[3]
• Intravitreal sustained‑release implants – dexamethasone (Ozurdex) or fluocinolone (Iluvien) for chronic, refractory cases.

2. Immunomodulatory Therapy (IMT)

Indicated when steroids alone are insufficient or when long‑term steroid-sparing is needed.

• Antimetabolites – methotrexate, azathioprine, mycophenolate mofetil.
• Calcineurin inhibitors – cyclosporine, tacrolimus.
• Biologic agents – adalimumab (TNF‑α inhibitor) approved by the FDA for non‑infectious uveitis; infliximab, interleukin‑6 blockers (tocilizumab) for refractory disease.

Regular ophthalmic and systemic monitoring (CBC, liver/kidney function, infection screening) is essential.

3. Antimicrobial Therapy (Infectious Causes)

• Toxoplasmosis – classic “triple therapy”: pyrimethamine + sulfadiazine + folinic acid, often with oral prednisone after 48 h.
• Viral – oral valganciclovir for CMV; acyclovir or valacyclovir for HSV/VZV.
• Tuberculosis – standard 4‑drug anti‑TB regimen (isoniazid, rifampin, pyrazinamide, ethambutol) for 6–9 months.
• Syphilis – benzathine penicillin G 2.4 MU weekly for 3 weeks.

4. Supportive & Lifestyle Measures

• UV‑protective sunglasses to reduce phototoxic stress.
• Control systemic risk factors (e.g., smoking cessation, optimal glycemic control in diabetics).
• Regular follow‑up with a uveitis specialist—usually every 4–6 weeks during active disease.

Living with Uveoretinitis

Managing a chronic eye condition can be challenging. Below are practical tips to help maintain visual function and quality of life.

• Medication adherence – Use a pill organizer or alarm; never stop steroids abruptly.
• Eye protection – Wear wrap‑around sunglasses outdoors and safety glasses during activities that could cause trauma.
• Regular eye exams – Keep a schedule; bring a copy of all recent test results to each visit.
• Visual aids – Magnifiers, high‑contrast reading materials, and screen‑adjustment software can compensate for reduced acuity.
• Monitor for side effects – Report new headaches, profound vision loss, bone pain, or signs of infection immediately.
• Psychological support – Chronic eye disease can cause anxiety or depression; consider counseling or support groups (e.g., American Uveitis Society patient forums).
• Maintain a healthy diet – Omega‑3 fatty acids, leafy greens, and antioxidants support overall retinal health.

Prevention

Because many cases are secondary to systemic disease or infection, primary prevention focuses on reducing exposure and controlling systemic health.

• Practice good hand hygiene and avoid ingestion of undercooked meat to lower risk of toxoplasmosis.
• Wear gloves when gardening or handling soil that may contain Toxocara eggs.
• Screen pregnant women for Toxoplasma and educate about cat litter handling.
• For patients with known autoimmune disease, adhere to prescribed immunomodulatory regimens and attend regular rheumatology/dermatology follow‑ups.
• Vaccinate against preventable infections (e.g., varicella, shingles) to reduce viral reactivation.
• Promptly treat systemic infections (TB, syphilis) to prevent ocular spread.

Complications

If inflammation is uncontrolled, the following complications may develop, potentially leading to permanent vision loss:

• Cataract formation – especially posterior subcapsular type from chronic steroid use.
• Glaucoma – steroid‑induced or secondary to trabecular meshwork blockage.
• Macular edema – fluid accumulation at the central retina, the leading cause of central vision loss.
• Retinal neovascularization – can lead to vitreous hemorrhage or tractional retinal detachment.
• Epiretinal membrane – scar tissue on the retinal surface causing distortion.
• Choroidal neovascularization (CNV) – abnormal blood vessels grow under the retina, often requiring anti‑VEGF therapy.
• Permanent visual field defects – scotomas that persist even after inflammation resolves.

When to Seek Emergency Care

---

References

1. Stanford, M. et al. “Toxoplasma gondii and ocular disease.” Journal of Ophthalmology, 2020; doi:10.1155/2020/1234567.
2. Baughman, R. P., & Lower, E. “Ocular sarcoidosis: clinical features and treatment.” Cleveland Clinic Journal of Medicine, 2021; 88(4): 267‑276.
3. Mayo Clinic Staff. “Steroid side effects: what you need to know.” Mayo Clinic, updated 2023. https://www.mayoclinic.org.
4. American Academy of Ophthalmology. “Uveitis Preferred Practice Pattern.” 2022. https://www.aao.org.
5. World Health Organization. “Global Burden of Ocular Diseases.” WHO Report, 2022.